Literature DB >> 17456850

Metabolic endotoxemia initiates obesity and insulin resistance.

Patrice D Cani1, Jacques Amar, Miguel Angel Iglesias, Marjorie Poggi, Claude Knauf, Delphine Bastelica, Audrey M Neyrinck, Francesca Fava, Kieran M Tuohy, Chantal Chabo, Aurélie Waget, Evelyne Delmée, Béatrice Cousin, Thierry Sulpice, Bernard Chamontin, Jean Ferrières, Jean-François Tanti, Glenn R Gibson, Louis Casteilla, Nathalie M Delzenne, Marie Christine Alessi, Rémy Burcelin.   

Abstract

Diabetes and obesity are two metabolic diseases characterized by insulin resistance and a low-grade inflammation. Seeking an inflammatory factor causative of the onset of insulin resistance, obesity, and diabetes, we have identified bacterial lipopolysaccharide (LPS) as a triggering factor. We found that normal endotoxemia increased or decreased during the fed or fasted state, respectively, on a nutritional basis and that a 4-week high-fat diet chronically increased plasma LPS concentration two to three times, a threshold that we have defined as metabolic endotoxemia. Importantly, a high-fat diet increased the proportion of an LPS-containing microbiota in the gut. When metabolic endotoxemia was induced for 4 weeks in mice through continuous subcutaneous infusion of LPS, fasted glycemia and insulinemia and whole-body, liver, and adipose tissue weight gain were increased to a similar extent as in high-fat-fed mice. In addition, adipose tissue F4/80-positive cells and markers of inflammation, and liver triglyceride content, were increased. Furthermore, liver, but not whole-body, insulin resistance was detected in LPS-infused mice. CD14 mutant mice resisted most of the LPS and high-fat diet-induced features of metabolic diseases. This new finding demonstrates that metabolic endotoxemia dysregulates the inflammatory tone and triggers body weight gain and diabetes. We conclude that the LPS/CD14 system sets the tone of insulin sensitivity and the onset of diabetes and obesity. Lowering plasma LPS concentration could be a potent strategy for the control of metabolic diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17456850     DOI: 10.2337/db06-1491

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  1913 in total

Review 1.  Mechanisms of inflammatory responses in obese adipose tissue.

Authors:  Shengyi Sun; Yewei Ji; Sander Kersten; Ling Qi
Journal:  Annu Rev Nutr       Date:  2012-03-09       Impact factor: 11.848

Review 2.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

3.  Temporal and Site-Specific Changes in Central Neuroimmune Factors During Rapid Weight Gain After Ovariectomy in Rats.

Authors:  Kathleen S Curtis; Kelly McCracken; Enith Espinosa; Johnson Ong; Daniel J Buck; Randall L Davis
Journal:  Neurochem Res       Date:  2018-07-20       Impact factor: 3.996

4.  Gut microbiome composition is linked to whole grain-induced immunological improvements.

Authors:  Inés Martínez; James M Lattimer; Kelcie L Hubach; Jennifer A Case; Junyi Yang; Casey G Weber; Julie A Louk; Devin J Rose; Gayaneh Kyureghian; Daniel A Peterson; Mark D Haub; Jens Walter
Journal:  ISME J       Date:  2012-10-04       Impact factor: 10.302

5.  Pyroglutamylated RF-amide peptide (QRFP) gene is regulated by metabolic endotoxemia.

Authors:  Christian Jossart; Mukandila Mulumba; Riccarda Granata; Davide Gallo; Ezio Ghigo; Sylvie Marleau; Marc J Servant; Huy Ong
Journal:  Mol Endocrinol       Date:  2013-01-01

6.  Precision-cut liver slices from diet-induced obese rats exposed to ethanol are susceptible to oxidative stress and increased fatty acid synthesis.

Authors:  Michael J Duryee; Monte S Willis; Courtney S Schaffert; Roger D Reidelberger; Anand Dusad; Daniel R Anderson; Lynell W Klassen; Geoffrey M Thiele
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-27       Impact factor: 4.052

Review 7.  The CF gastrointestinal microbiome: Structure and clinical impact.

Authors:  Geraint B Rogers; Michael R Narkewicz; Lucas R Hoffman
Journal:  Pediatr Pulmonol       Date:  2016-10

8.  Interleukin-23 promotes intestinal T helper type17 immunity and ameliorates obesity-associated metabolic syndrome in a murine high-fat diet model.

Authors:  Larissa M S Martins; Malena M Perez; Camila A Pereira; Frederico R C Costa; Murilo S Dias; Rita C Tostes; Simone G Ramos; Marcel R de Zoete; Bernhard Ryffel; João S Silva; Daniela Carlos
Journal:  Immunology       Date:  2018-05-02       Impact factor: 7.397

Review 9.  Microbiota and metabolic diseases.

Authors:  Alessia Pascale; Nicoletta Marchesi; Cristina Marelli; Adriana Coppola; Livio Luzi; Stefano Govoni; Andrea Giustina; Carmine Gazzaruso
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

Review 10.  The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus.

Authors:  Mehmet Kanbay; Emine M Onal; Baris Afsar; Tuncay Dagel; Aslihan Yerlikaya; Adrian Covic; Nosratola D Vaziri
Journal:  Int Urol Nephrol       Date:  2018-05-04       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.